What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protein naturally present in human gastric juice. It was first identified and characterized by Predrag Sikiric and colleagues at the University of Zagreb, Croatia, who have published the majority of the research on this compound since 1993.
The "body protection" name reflects the peptide's origin in the gastrointestinal tract, where the parent protein is thought to play a role in maintaining mucosal integrity. BPC-157 is a fragment of this larger protein, isolated and synthesized for research. Unlike many peptides, BPC-157 is remarkably stable — it remains intact in human gastric juice for more than 24 hours, which is unusual for a peptide and supports its potential for oral administration.
Amino Acid Sequence
Sequence analysis: BPC-157 contains 4 prolines (creating backbone rigidity), 2 aspartates and 1 glutamate (negative charges), 1 lysine (positive charge), and 3 glycines (maximum flexibility). The high proline content contributes to its resistance to proteolytic degradation — proline's rigid cyclic structure makes adjacent peptide bonds less accessible to proteases. The net charge of −2 at physiological pH makes it hydrophilic and water-soluble.
Mechanism of Action
BPC-157 exerts its effects through multiple interconnected signaling pathways. The two best-characterized are the VEGFR2-dependent pathway and the Src-Caveolin-1-eNOS pathway, both of which converge on nitric oxide production and angiogenesis.
Primary Pathway: VEGFR2 → Akt → eNOS
BPC-157 does not directly produce VEGF. Instead, it upregulates VEGFR2 expression — increasing the number of VEGF receptors on endothelial cell surfaces, making these cells more responsive to the body's own VEGF signals. This is a critical distinction: BPC-157 amplifies the body's existing repair signaling rather than introducing an external growth signal.
Secondary Pathway: Src-Caveolin-1-eNOS
Independent of VEGF, BPC-157 also activates eNOS through disruption of the Caveolin-1/eNOS inhibitory complex. In resting endothelial cells, Caveolin-1 binds to eNOS and keeps it inactive. BPC-157 promotes Src kinase-mediated phosphorylation of Caveolin-1, releasing eNOS from its inhibition and allowing sustained nitric oxide production. This pathway was demonstrated by an independent research group (Hsieh et al., 2020, Scientific Reports), providing important validation from outside the original Zagreb research group.
Additional Mechanisms
| Pathway | Effect | Significance |
|---|---|---|
| ERK1/2 activation | Promotes cell proliferation and migration | Accelerates wound closure and tissue remodeling |
| Growth hormone receptor upregulation | Enhances tissue sensitivity to GH | May amplify the body's growth/repair axis |
| COX-2 modulation | Anti-inflammatory without full COX inhibition | Reduces inflammation while preserving protective prostaglandins |
| NOS1/NOS3 upregulation, NOS2 downregulation | Increases protective NO, decreases inflammatory NO | Balances the NO system rather than broadly increasing it |
| FAK-paxillin activation | Promotes cell adhesion and migration | Helps cells migrate to injury sites for repair |
Preclinical Evidence
Over 544 studies have been published on BPC-157 since 1993. The vast majority are preclinical (animal models and in vitro). Here are the major study areas and their evidence levels:
| Study Area | Models Used | Key Findings | Studies |
|---|---|---|---|
| Tendon healing | Rat Achilles tendon transection | Accelerated tendon-to-bone healing, increased collagen organization, enhanced mechanical strength | 12+ |
| Muscle healing | Rat crush injury, laceration | Faster muscle fiber regeneration, reduced fibrosis (scar tissue), functional recovery | 10+ |
| Ligament repair | Rat MCL transection | Enhanced ligament biomechanical properties, improved collagen deposition | 5+ |
| Bone healing | Rat segmental bone defect | Accelerated fracture consolidation, enhanced osteoblast activity via VEGFR2-NO signaling | 8+ |
| GI protection | Rat gastric ulcer, IBD models | Accelerated ulcer healing, maintained mucosal integrity, reduced inflammatory markers | 50+ |
| Nerve regeneration | Rat sciatic nerve crush | Improved nerve fiber regeneration, enhanced functional recovery, neuroprotective effects | 6+ |
| Vascular protection | Rat ischemia-reperfusion | Accelerated blood flow recovery, reduced ischemic damage, stabilized vascular tone | 15+ |
| Anti-inflammatory | Various inflammatory models | Reduced TNF-α, IL-6, IL-1β; modulated NF-κB pathway | 20+ |
Over 80% of all published BPC-157 research originates from a single research group (Sikiric et al., University of Zagreb). While the studies are well-conducted, the lack of broad independent replication is a significant limitation. The 2020 Src-Caveolin-1-eNOS paper from Taiwan (Hsieh et al.) and a 2024 narrative review represent important independent confirmations, but more are needed.
Human Data
As of 2026, human clinical data on BPC-157 is extremely limited. Only three pilot studies exist:
| Study | Condition | N | Finding |
|---|---|---|---|
| Intraarticular knee pain | Knee osteoarthritis | Small pilot | Reported pain reduction; no control group |
| Interstitial cystitis | Bladder pain syndrome | Small pilot | Symptom improvement reported |
| IV pharmacokinetics/safety | Healthy volunteers | Phase I-like | No serious adverse events; short plasma half-life (<30 min) |
No Phase II or Phase III randomized controlled trials have been completed. This means BPC-157's efficacy and safety in humans remain unproven by regulatory standards, despite the extensive preclinical data. The pharmacokinetic study showed a short plasma half-life (less than 30 minutes in rats and dogs), raising questions about optimal dosing frequency.
Routes of Administration & Dosing
Subcutaneous Injection
The most common route in clinical use. Typically injected near the site of injury for localized effect. Preclinical studies consistently use 10 μg/kg or 10 ng/kg body weight. Human dosing in practice typically ranges from 200–500 μg per injection, once or twice daily, though this is extrapolated from animal data and not established by clinical trials.
Oral Administration
BPC-157 is unusual among peptides in that it demonstrates meaningful oral bioactivity. Its stability in gastric juice (>24 hours) and the extensive gut-healing data suggest oral administration is viable, particularly for gastrointestinal applications. Capsule formulations (typically 200–500 μg) are commercially available, though not FDA-regulated.
Most peptides are destroyed by stomach acid and digestive enzymes, making oral administration useless. BPC-157's unusual resistance to gastric degradation is likely due to its high proline content (4 of 15 residues) — proline's cyclic structure makes adjacent peptide bonds resistant to many proteases — and its origin in gastric juice, where it evolved to function in that harsh environment.
Safety & Concerns
In preclinical studies, BPC-157 has shown a favorable safety profile with no reported organ toxicity, mutagenicity, or significant adverse effects at standard research doses. However, several important concerns remain:
Angiogenesis and cancer risk: Because BPC-157 promotes blood vessel growth, theoretical concerns exist about whether it could promote tumor angiogenesis and accelerate cancer growth. Some in vitro data suggest BPC-157 may actually have anti-tumor properties (inhibiting VEGF signaling in melanoma cell lines), but this remains debated. Researchers have pointed out that BPC-157 appears to promote controlled, physiological angiogenesis rather than the uncontrolled type seen in tumors.
Limited dose-response data: Most studies use only one or two doses (10 μg/kg or 10 ng/kg). The effects of higher, repeated, or long-term doses are largely unknown. No chronic toxicity studies have been published.
Quality control: BPC-157 is not manufactured under pharmaceutical-grade conditions for consumer use. Products available online vary widely in purity, and contamination is a risk with any research-grade peptide.
Regulatory Status
| Jurisdiction | Status |
|---|---|
| FDA (United States) | Not approved for any indication. Not a dietary supplement. Classified as a research chemical. FDA has issued warning letters to companies marketing BPC-157 for human use. |
| WADA (World Anti-Doping) | Banned under category S0 (non-approved substances) since 2022. Athletes testing positive face sanctions. |
| TGA (Australia) | Not approved. Listed as a Schedule 4 substance (prescription-only). |
| EMA (Europe) | Not approved. No marketing authorization in any EU member state. |
BPC-157 vs TB-500
BPC-157 and TB-500 (Thymosin Beta-4 fragment) are the two most commonly discussed healing peptides. Here's how they compare:
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Size | 15 amino acids (1,419 Da) | 43 amino acids (4,963 Da) |
| Origin | Human gastric juice protein | Thymus gland (Thymosin β4) |
| Primary mechanism | VEGFR2-Akt-eNOS → angiogenesis | G-actin sequestration → cell migration |
| Key action | Builds new blood vessels to injured tissue | Promotes cell migration to injury site |
| Oral bioavailability | Yes (stable in gastric juice) | No (injection only) |
| Best for | Tendons, gut, localized injuries | Systemic inflammation, muscle, cardiac |
| Human data | 3 pilot studies | Minimal |
| Combined use | Commonly stacked together in clinical practice (angiogenesis + cell migration = complementary mechanisms) | |
Analyze BPC-157 in the Design Lab
Want to see BPC-157's biochemical properties calculated in real time? Load its sequence into the Peptide Design Lab to see molecular weight, charge at any pH, hydrophobicity profile, isoelectric point, and stability warnings — or ask the AI advisor about modification strategies.